NDT Advance Access originally published online on April 6, 2005
Nephrology Dialysis Transplantation 2005 20(6):1048-1056; doi:10.1093/ndt/gfh813
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chronic kidney disease as cause of cardiovascular morbidity and mortality
1 Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium, 2 Divisions of Clinical Pharmacology and Nephrology, University of Picardie and Amiens, University Hospital, Amiens, France, 3 Laboratory of Functional Genomics, UPR 2580 of CNRS, Montpellier, France and 4 Department of Nephrology, Clinical Center, University Hospital, Skopje, Macedonia
Correspondence and offprint requests to: Raymond Vanholder, MD, PhD, Nephrology Section, 0K12, University Hospital, De Pintelaan 185, B-9000 Gent, Belgium. Email: raymond.vanholder{at}ugent.be
To make an evidence-based evaluation of the relationship between kidney failure and cardiovascular risk, we reviewed the literature obtained from a PubMed search using pre-defined keywords related to both conditions and covering 18 years (1986 until end 2003). Eighty-five publications, covering 552 258 subjects, are summarized. All but three studies support a link between kidney dysfunction and cardiovascular risk. More importantly, the association is observed very early during the evolution of renal failure: an accelerated cardiovascular risk appears at varying glomerular filtration rate (GFR) cut-off values, which were 
60 ml/min in at least 20 studies. Many studies lacked a clear definition of cardiovascular disease and/or used a single determination of serum creatinine or GFR as an index of kidney function, which is not necessarily corresponding to well-defined chronic kidney disease. In six studies, however, chronic kidney dysfunction and cardiovascular disease were well defined and the results of these confirm the impact of kidney dysfunction. It is concluded that there is an undeniable link between kidney dysfunction and cardiovascular risk and that the presence of even subtle kidney dysfunction should be considered as one of the conditions necessitating intensive prevention of this cardiovascular risk.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Vanholder and L. A. Pedrini All high-flux membranes are equal but some high-flux membranes are less equal than others Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1481 - 1483. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vanholder, U. Baurmeister, P. Brunet, G. Cohen, G. Glorieux, J. Jankowski, and for the European Uremic Toxin Work Group A Bench to Bedside View of Uremic Toxins J. Am. Soc. Nephrol., May 1, 2008; 19(5): 863 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kronborg, M. Solbu, I. Njolstad, I. Toft, B. O. Eriksen, and T. Jenssen Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study Nephrol. Dial. Transplant., April 9, 2008; (2008) gfn148v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. C. Taes, B. Marescau, A. De Vriese, P. P. De Deyn, E. Schepers, R. Vanholder, and J. R. Delanghe Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1330 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Davis, W. E. Harmon, J. Himmelfarb, T. Hostetter, N. Powe, P. Smedberg, L. A. Szczech, P. S. Aronson, and for the American Society of Nephrology Public Poli World Kidney Day 2008: Think Globally, Speak Locally J. Am. Soc. Nephrol., March 1, 2008; 19(3): 413 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vanholder, S. V. Laecke, F. Verbeke, G. Glorieux, and W. V. Biesen Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies NDT Plus, February 1, 2008; 1(1): 2 - 10. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Novak and L. A. Szczech Feast and Famine: Epidemiology and Clinical Trials in Chronic Kidney Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
F. Addabbo, F. Mallamaci, D. Leonardis, R. Tripepi, G. Tripepi, M. S. Goligorsky, and C. Zoccali Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3521 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cohen, G. Glorieux, P. Thornalley, E. Schepers, N. Meert, J. Jankowski, V. Jankowski, A. Argiles, B. Anderstam, P. Brunet, et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3381 - 3390. [Full Text] [PDF]
|
|
|
|
|
|
F. Verbeke, W. Van Biesen, P. Peeters, L. M. Van Bortel, and R. C. Vanholder Arterial stiffness and wave reflections in renal transplant recipients Nephrol. Dial. Transplant., October 1, 2007; 22(10): 3021 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. B. Nanayakkara, C. van Guldener, P. M. ter Wee, P. G. Scheffer, F. J. van Ittersum, J. W. Twisk, T. Teerlink, W. van Dorp, and C. D. A. Stehouwer Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study Arch Intern Med, June 25, 2007; 167(12): 1262 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Denhaerynck, D. Manhaeve, F. Dobbels, D. Garzoni, C. Nolte, and S. De Geest PREVALENCE AND CONSEQUENCES OF NONADHERENCE TO HEMODIALYSIS REGIMENS Am. J. Crit. Care., May 1, 2007; 16(3): 222 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Van Biesen, D. De Bacquer, F. Verbeke, J. Delanghe, N. Lameire, and R. Vanholder The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years Eur. Heart J., February 2, 2007; 28(4): 478 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schepers, N. Meert, G. Glorieux, J. Goeman, J. Van der Eycken, and R. Vanholder P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production Nephrol. Dial. Transplant., February 1, 2007; 22(2): 592 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nikolov, N. Joki, T. Drueke, and Z. Massy Beyond phosphate--role of uraemic toxins in cardiovascular calcification Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3354 - 3357. [Full Text] [PDF]
|
|
|
|
|
|
B. Kiberd The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2967 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zalba, A. Fortuno, and J. Diez Oxidative stress and atherosclerosis in early chronic kidney disease Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2686 - 2690. [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, L. Zuo, F. Wang, M. Wang, S. Wang, J. Lv, L. Liu, and H. Wang Cardiovascular Disease in Early Stages of Chronic Kidney Disease in a Chinese Population J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2617 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Halbesma, D.-S. Kuiken, A. H. Brantsma, S. J.L. Bakker, J. F.M. Wetzels, D. De Zeeuw, P. E. De Jong, R. T. Gansevoort, and for the PREVEND Study Group Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2582 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Soveri, H. Holdaas, A. Jardine, C. Gimpelewicz, B. Staffler, and B. Fellstrom Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2282 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jones, P. Roderick, S. Harris, and M. Rogerson Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2133 - 2143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Svensson, E. B. Schmidt, K. A. Jorgensen, J. H. Christensen, and on behalf of the OPACH Study Group N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 780 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.S. MacGregor, D.E. Boag, and A. Innes Chronic kidney disease: evolving strategies for detection and management of impaired renal function QJM, June 1, 2006; 99(6): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Uhlig, E. M. Balk, J. Lau, and A. S. Levey Clinical Practice Guidelines in nephrology--for worse or for better Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1145 - 1153. [Full Text] [PDF]
|
|
|
|
|
|
W. Van Biesen, R. Vanholder, N. Veys, F. Verbeke, J. Delanghe, D. De Bacquer, and N. Lameire The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes Nephrol. Dial. Transplant., January 1, 2006; 21(1): 77 - 83. [Abstract] [Full Text] [PDF]
|
|